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In recent years, there has been an increased research interest in continuous processing of biopharmaceuticals. 
This is not only due to technological advancements and better economics, but can also be attributed to 
enhanced quality control, for example facilitated by reduction or elimination of intermediate storage. Thus, these 
processes allow to improve both the product’s profitability and the patient’s safety. In case of downstream 
processing, multi-column counter-current processes have emerged both for capture (e.g. CaptureSMB, 3C-
PCC) and polishing applications (e.g. SMB, MCSGP) enabling these advantages. With the exception of the well-
established AEX flow-through, polishing steps are typically carried out in bind-elute mode. This is also true for 
the continuous processes such as SMB or MCSGP. In the latter case, the part of the eluate with high enough 
purity is obtained as final product, while on either side of it impure sections containing significant amounts of 
product are recycled onto the second column. This allows to meet purity requirements while not sacrificing yield 
when high resolutions are hard to achieve. An example of such a situation is the separation of charge variants of 
antibodies, which have been shown to have different immunogenicity and efficacy [1, 2]. While tuning the charge 
variant profile for a novel active pharmaceutical ingredient is currently not relevant from a regulatory point of 
view, it becomes very important with regards to biosimilars, where there is a target profile to be met. Industrial 
and academic interest in this kind of biopharmaceutical has increased over the past years due to the expiration 
of patents of blockbuster drugs and the necessity for processes to meet the originator’s properties. In this study, 
we show how selection of product and recycle window of the MCSGP process impact the charge variant profile 
of an industrial mAb and therefore the capability of the process to tune the profile while conserving high yields. 
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